Jan. 15, 2026 -- Juvenile Diabetes Cure Alliance (JDCA), a 501(c)(3) nonprofit solely focused on accelerating a cure for type 1 diabetes, announced the release of the 14th annual State of the Cure for Type 1 Diabetes (SOTC). This is the first publication to highlight the shift of cell supply research from the nonprofit to the commercial domain. Type 1 diabetes is a chronic autoimmune condition where insulin-producing cells are destroyed by the immune system, requiring lifelong dependence on ex

Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential for advanced cancer patients with no treatment options Among all efficacy-evaluable monotherapy patients comprising 18 different cancers (n=55), ORR was19% with MDNA11 as a 2L/3L treatment and 24% when MDNA11 was the next treatment post-ICI failure Based on these data, Medicenna plans to complete ABIL

Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points Jan. 14, 2026 -- C4 Therapeutics, Inc. (C4T) (Nas

Jan. 12, 2026 -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen’s continued execution toward a scalable, established, multi-program cell therapy development organization. In 2025, Tevogen advanced its proprietary ExacTcell™ platform, expanded its cytotoxic T lymphocyte (CTL) pipeline across multiple viral and oncology indications, and ad

-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases- -Starting 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities- Jan. 12, 2026 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical compa

1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for Early Q2 2026 Initial Proof-of-Concept for ALLO-329, the Dual CD19/CD70 AlloCAR T Leveraging the Dagger® Technology to Reduce or Eliminate Lymphodepletion in the Treatment of Autoimmune Dis

Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approximately $85.6 million in cash and cash equivalents on hand, supporting execution across planned 2026 milestones Received gross proceeds of $23.0 million from exercises of Tranche A warrants from August 2025 financing, with cash runway into early 2027 Jan. 05, 2026 -- Fractyl Health, Inc. (Nasdaq: GUT

Jan. 05, 2026 -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a publication in the peer-reviewed Journal of Clinical Endocrinology and Metabolism (JCEM). The paper, titled, “Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal Period Study,” details results from the 16-week randomized withdrawal study (C602

Jan. 07, 2026 -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) an innovative biotechnology company focused on developing transformative treatments for chronic inflammatory conditions and debilitating retinal diseases, today provides an update on its preclinical programs in 2025 and its planned clinical activities in 2026 for its two lead product candidates EOM613 and EOM147. In 2025, the company completed IND-enabling toxicological and dosing preclinical animal studies for EOM613 with f

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operation